why choose us

First received: December 21, 2022

Clinical Trial: DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Small Cell Lung Cancer Extensive Stage

Study Type: INTERVENTIONAL


Official Title: A First in Human Dose Escalation and Cohort Expansion Study of DLL3-directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer

Brief Summary: This is a phase 1, first-in-human, open-label, multicenter, dose escalation and expansion study of DLL3-targeted chimeric antigen receptor T-cells in subjects with extensive stage small cell lung cancer or large cell neuroendocrine lung cancer.

Read more